Bromocriptine and Stomach Cancer in Rats
Author Information
Author(s): H. Tishi, M. Baba, M. Tatsuta, S. Okuda, H. Taniguchi
Primary Institution: The Center for Adult Diseases, Osaka, Japan
Hypothesis
Does the dopamine agonist bromocriptine promote gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats?
Conclusion
Bromocriptine treatment significantly increased the incidence and number of gastric cancers in rats.
Supporting Evidence
- Bromocriptine treatment resulted in a significant increase in the incidence and number of gastric cancers.
- All tumors induced were identified histologically as adenocarcinomas.
- The labelling index of gastric mucosa was significantly higher in bromocriptine-treated groups.
Takeaway
This study found that a drug called bromocriptine can make rats more likely to get stomach cancer when they are given a certain chemical.
Methodology
Wistar rats were treated with MNNG for 25 weeks and then given bromocriptine or olive oil every other day for 27 weeks, followed by autopsy and histological examination.
Limitations
The study was conducted on a specific strain of rats, which may limit the generalizability of the findings.
Participant Demographics
Young male Wistar rats, 6 weeks old at the start of the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website